DK2949361T3 - C-19 steroider til behandling af cellulit - Google Patents
C-19 steroider til behandling af cellulit Download PDFInfo
- Publication number
- DK2949361T3 DK2949361T3 DK15172134.7T DK15172134T DK2949361T3 DK 2949361 T3 DK2949361 T3 DK 2949361T3 DK 15172134 T DK15172134 T DK 15172134T DK 2949361 T3 DK2949361 T3 DK 2949361T3
- Authority
- DK
- Denmark
- Prior art keywords
- compound
- use according
- alkyl
- hydrogen
- double bond
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Claims (11)
1. Forbindelse valgt fra forbindelser som har den følgende formel:
hvor a, b og c henholdsvist betyder, uafhængigt fra hinanden, en enkelt binding eller en dobbelt binding, med det forbehold at mindst en afa, b og c repræsenterer en dobbelt binding, og med det forbehold at hvis a er enkelt binding og b er dobbelt binding er R2 ikke H; Ri er hydrogen eller Ci til Ce alkyl; R2 er OR5, hvor Rs er hydrogen eller Ci til C6 ligekædet eller forgrenet alkyl; R3 er, i tilfælde hvor c er en enkelt binding, hydrogen eller Ci til Ce alkyl, eller i tilfælde hvor c er en dobbelt binding, CHRs, hvor Rs er den samme som defineret før; R4 er hydrogen, Ci til C6 alkyl, phenyl ikke-substitueret eller substitueret med Ci til C6 alkyl, eller COR6 acylgruppe (hvor R6 er hydrogen; Ci til Ce ligekædet eller forgrenet alkyl; phenyl eller benzoyl henholdsvis ikke-substitueret eller substitueret med Ci til Ce alkyl); og salte deraf; til anvendelse i profylaksen og/eller behandlingen af cellulit.
2. Forbindelsen til anvendelse ifølge krav 1, hvor forbindelsen defineres af a og c værende en enkelt binding, b værende en dobbelt binding, og R2 værende OR5, OR5 værende som defineret i krav 1.
3. Forbindelsen til anvendelse ifølge krav 1 eller 2, hvor forbindelsen anvendes topikalt.
4. Forbindelsen til anvendelse ifølge et hvilket som helst af de foregående krav, hvor profylaksen og/eller behandlingen fremstilles underen betingelse således at 10 en forbedret anabolsk aktivitet opnås, mens androgene effekter mindskes.
5. Forbindelsen til anvendelse ifølge krav 4, hvor opnåelsen afen forbedret anabolsk aktivitet associeres med en hvilken som helst af collagenstabilisering, -øgning og -forstærkning. 15
6. Forbindelsen til anvendelse ifølge krav 4 eller 5, hvor opnåelsen afen forbedret anabolsk aktivitet bestemmes af forbedring af collagenproduktion.
7. Forbindelsen til anvendelse ifølge et hvilket som helst af de foregående krav, 20 hvor profylaksen og/eller behandlingen fremstilles under en betingelse således at en blokeringseffekt på AR mod binding af naturlig androgen opnås.
8. Forbindelsen til anvendelse ifølge et hvilket som helst af de foregående krav, hvor profylaksen og/eller behandlingen fremstilles under en betingelse således at 25 de følgende effekter eller egenskaber, alene eller i kombination, opnås: • forbindelsen ikke er aromatiseret med aromatase; • forbindelsen ikke er reduceret med 5a-reduktase; • forbindelsen inhiberer 5a-reduktase; • i formen af sin C-17 oxiderede metabolit, udviser forbindelsen forbedret aromatasehæmning.
9. Forbindelsen til anvendelse ifølge et hvilket som helst af de foregående krav, 5 hvor forbindelsen er 4-hydroxytestosteron eller dets salte eller estere af 4- hydroxytestosteron i hvilket FU ifølge krav 1 er en COR6 acylgruppe ifølge krav 1.
10. Forbindelsen til anvendelse ifølge et hvilket som helst af de foregående krav, hvor forbindelsen anvendes i en sammensætning endvidere omfattende 10 dimethylisosorbid.
11. Forbindelsen til anvendelse ifølge krav 10 i formen af en topikal formulering.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15172134.7A EP2949361B1 (en) | 2007-11-13 | 2007-11-13 | C-19 steroids for treating cellulite |
EP07022016.5A EP2060300B1 (en) | 2007-11-13 | 2007-11-13 | C-19 steroids for therapeutic uses |
EP12171940.5A EP2500062B1 (en) | 2007-11-13 | 2007-11-13 | C-19 steroids for specific therapeutic uses |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2949361T3 true DK2949361T3 (da) | 2017-07-03 |
Family
ID=39183133
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12171940.5T DK2500062T3 (da) | 2007-11-13 | 2007-11-13 | C-19-steroider til specifikke terapeutiske anvendelser |
DK15172134.7T DK2949361T3 (da) | 2007-11-13 | 2007-11-13 | C-19 steroider til behandling af cellulit |
DK07022016.5T DK2060300T3 (da) | 2007-11-13 | 2007-11-13 | C-19-steroider til terapeutiske anvendelser |
DK12194964.8T DK2564900T3 (da) | 2007-11-13 | 2008-11-12 | C-19-steroider til terapeutiske anvendelser |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12171940.5T DK2500062T3 (da) | 2007-11-13 | 2007-11-13 | C-19-steroider til specifikke terapeutiske anvendelser |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK07022016.5T DK2060300T3 (da) | 2007-11-13 | 2007-11-13 | C-19-steroider til terapeutiske anvendelser |
DK12194964.8T DK2564900T3 (da) | 2007-11-13 | 2008-11-12 | C-19-steroider til terapeutiske anvendelser |
Country Status (17)
Country | Link |
---|---|
US (1) | US10265328B2 (da) |
EP (5) | EP2949361B1 (da) |
JP (1) | JP6025301B2 (da) |
KR (2) | KR20160036100A (da) |
CN (1) | CN101854979B (da) |
AU (1) | AU2008323199B2 (da) |
CA (1) | CA2705533C (da) |
CY (1) | CY1116496T1 (da) |
DK (4) | DK2500062T3 (da) |
ES (4) | ES2539800T3 (da) |
HK (1) | HK1148704A1 (da) |
HR (1) | HRP20150715T1 (da) |
HU (2) | HUE027440T2 (da) |
PL (4) | PL2949361T3 (da) |
PT (3) | PT2500062E (da) |
SI (1) | SI2564900T1 (da) |
WO (1) | WO2009062683A1 (da) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2964323B1 (fr) * | 2010-09-08 | 2012-11-09 | Jean Pierre Raynaud | Utilisation de la testosterone chez un patient en deficit androgenique et atteint d'un cancer de la prostate |
WO2012156820A1 (en) * | 2011-05-15 | 2012-11-22 | Trimel Pharmaceuticals Corp. | Intranasal testosterone bio-adhesive gel formulations and use thereof for treating male hypogonadism |
WO2014165971A1 (en) * | 2013-04-10 | 2014-10-16 | Glycobiosciences, Inc. | Topical nutraceutical composition |
HUE037698T2 (hu) * | 2014-12-30 | 2018-09-28 | Curadis Gmbh | C-19 szteroidok neovaszkularizáció gátlására |
EP3632445A1 (en) * | 2018-10-04 | 2020-04-08 | Curadis GmbH | Combinations with a c-19 steroid for treating cancers |
CN112972465B (zh) * | 2021-02-22 | 2022-09-13 | 复旦大学附属中山医院 | 一种雄激素受体拮抗剂在制备治疗心血管疾病药物中的应用 |
KR102554865B1 (ko) | 2021-10-05 | 2023-07-12 | 경상북도(농업기술원) | 친환경 덩굴 절단 파쇄장치 |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2762818A (en) | 1955-05-26 | 1956-09-11 | Searle & Co | 4-hydroxytestosterone and esters thereof |
DE3121153A1 (de) * | 1981-05-22 | 1982-12-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | "verwendung von aromatase-hemmern zur prophylaxe und therapie der prostatahyperplasie" |
DE3121152A1 (de) * | 1981-05-22 | 1982-12-09 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie" |
JPS62132810A (ja) | 1985-12-05 | 1987-06-16 | Shiseido Co Ltd | 化粧料 |
GB8721384D0 (en) | 1987-09-11 | 1987-10-21 | Erba Farmitalia | 17-substituted andro-sta-1 4-dien-3-one derivatives |
US4895715A (en) * | 1988-04-14 | 1990-01-23 | Schering Corporation | Method of treating gynecomastia |
GB9021546D0 (en) | 1990-10-04 | 1990-11-21 | Beecham Group Plc | Novel composition |
WO1992007586A1 (en) | 1990-10-31 | 1992-05-14 | Beecham Group Plc | Topical composition with retinoid penetration enhancer |
DE4405898A1 (de) | 1994-02-18 | 1995-08-24 | Schering Ag | Transdermale therapeutische Systeme enthaltend Sexualsteroide |
US5824326A (en) | 1997-06-27 | 1998-10-20 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Activity enhancement of ferulic acid with dimethyl isosorbride in cosmetic compositions |
CA2670236C (en) * | 1999-09-30 | 2012-06-05 | Hollis-Eden Pharmaceuticals, Inc. | Therapeutic treatment of androgen receptor driven conditions |
GB9930839D0 (en) | 1999-12-30 | 2000-02-16 | Pharmacia & Upjohn Spa | Process for treating gynecomastia |
GB0012293D0 (en) | 2000-05-23 | 2000-07-12 | Astrazeneca Ab | Pharmaceutical combination |
US6242436B1 (en) * | 2000-06-15 | 2001-06-05 | William Charles Llewellyn | Use of 5alpha-androstanediol or 5alpha-androstanedione to increase dihydrotestosterone levels in humans |
CA2459943A1 (en) | 2001-09-21 | 2003-04-03 | Merck & Co., Inc. | Androstanes as androgen receptor modulators |
US6586417B1 (en) * | 2002-04-22 | 2003-07-01 | Nutrisport Pharmacal, Inc. | Ester and ether derivatives of 4-hydroxy 4-androstene-3,17-dione and a method for the regulation of athletic function in humans |
US20030199487A1 (en) | 2002-04-22 | 2003-10-23 | Mr. Vince Paternoster | Ester and ether derivatives of 4-hydroxytestosterone and a method for the regulation of athletic function in humans |
US20030229063A1 (en) | 2002-06-05 | 2003-12-11 | Llewellyn William Charles | Use of 4-hydroxytestosterone to lower estrogen levels in humans |
CN1726034A (zh) * | 2002-10-15 | 2006-01-25 | 田纳西大学研究基金会 | 亚甲基桥连的选择性雄激素受体调节剂及其应用方法 |
US20060018937A1 (en) * | 2002-10-25 | 2006-01-26 | Foamix Ltd. | Steroid kit and foamable composition and uses thereof |
AU2004285134B2 (en) | 2003-10-21 | 2012-01-19 | Dyad Pharmaceutical Corporation | Methods and compositions for treating 5alpha-reductase type 1 and type 2 dependent conditions |
EP1692317A4 (en) | 2003-12-12 | 2007-12-19 | Univ Rochester | NON-ANDROGENO-DEPENDENT ROLES FOR ANDROGEN RECEPTOR AND NON-ANDROGENIC ASSOCIATED INHIBITORS OF ANDROGEN RECEPTOR |
JP2008007404A (ja) * | 2004-10-08 | 2008-01-17 | Nippon Kayaku Co Ltd | 新規ピリジン誘導体 |
US20090062258A1 (en) * | 2005-02-03 | 2009-03-05 | Takeda Pharmaceutical Company Limited | Fused pyrimidine derivative and use thereof |
WO2006084312A1 (en) | 2005-02-09 | 2006-08-17 | Acrux Dds Pty Ltd | Method of promoting hair growth |
JP4755845B2 (ja) | 2005-04-28 | 2011-08-24 | 共栄化学工業株式会社 | テストステロン−5α−リダクターゼ阻害剤及びテストステロン−5α−リダクターゼ阻害剤を含有する化粧料。 |
EP1854465A1 (en) * | 2006-05-12 | 2007-11-14 | Alexander Tobias Teichmann | Use of 4,17 beta-dihydroxyandrost-4-ene-3-one for treating cancers |
DK2060261T3 (da) * | 2007-11-13 | 2016-06-13 | Athenion Ag | C-19-steroider til kosmetisk anvendelse |
-
2007
- 2007-11-13 PT PT121719405T patent/PT2500062E/pt unknown
- 2007-11-13 DK DK12171940.5T patent/DK2500062T3/da active
- 2007-11-13 EP EP15172134.7A patent/EP2949361B1/en not_active Not-in-force
- 2007-11-13 EP EP12171940.5A patent/EP2500062B1/en active Active
- 2007-11-13 ES ES07022016.5T patent/ES2539800T3/es active Active
- 2007-11-13 PL PL15172134T patent/PL2949361T3/pl unknown
- 2007-11-13 PL PL12171940T patent/PL2500062T3/pl unknown
- 2007-11-13 EP EP07022016.5A patent/EP2060300B1/en active Active
- 2007-11-13 DK DK15172134.7T patent/DK2949361T3/da active
- 2007-11-13 ES ES15172134.7T patent/ES2628507T3/es active Active
- 2007-11-13 PT PT70220165T patent/PT2060300E/pt unknown
- 2007-11-13 HU HUE12171940A patent/HUE027440T2/en unknown
- 2007-11-13 DK DK07022016.5T patent/DK2060300T3/da active
- 2007-11-13 ES ES12171940.5T patent/ES2547339T3/es active Active
- 2007-11-13 PL PL07022016T patent/PL2060300T3/pl unknown
-
2008
- 2008-11-12 CN CN200880115837.3A patent/CN101854979B/zh not_active Expired - Fee Related
- 2008-11-12 US US12/734,616 patent/US10265328B2/en not_active Expired - Fee Related
- 2008-11-12 EP EP20120194964 patent/EP2564900B1/en active Active
- 2008-11-12 DK DK12194964.8T patent/DK2564900T3/da active
- 2008-11-12 EP EP10165423A patent/EP2260903A1/en not_active Ceased
- 2008-11-12 KR KR1020167007505A patent/KR20160036100A/ko active Search and Examination
- 2008-11-12 WO PCT/EP2008/009541 patent/WO2009062683A1/en active Application Filing
- 2008-11-12 HU HUE12194964A patent/HUE025577T2/en unknown
- 2008-11-12 KR KR1020107010503A patent/KR20100094975A/ko active Search and Examination
- 2008-11-12 AU AU2008323199A patent/AU2008323199B2/en not_active Ceased
- 2008-11-12 PT PT121949648T patent/PT2564900E/pt unknown
- 2008-11-12 CA CA2705533A patent/CA2705533C/en not_active Expired - Fee Related
- 2008-11-12 JP JP2010533487A patent/JP6025301B2/ja not_active Expired - Fee Related
- 2008-11-12 PL PL12194964T patent/PL2564900T3/pl unknown
- 2008-11-12 SI SI200831456T patent/SI2564900T1/sl unknown
- 2008-11-12 ES ES12194964.8T patent/ES2543047T3/es active Active
-
2011
- 2011-03-18 HK HK11102722.8A patent/HK1148704A1/zh not_active IP Right Cessation
-
2015
- 2015-07-01 HR HRP20150715TT patent/HRP20150715T1/hr unknown
- 2015-07-16 CY CY20151100620T patent/CY1116496T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2949361T3 (da) | C-19 steroider til behandling af cellulit | |
KR101776544B1 (ko) | 화장용 및 기타 용도용 c-19 스테로이드 | |
Rasmusson et al. | Therapeutic control of androgen action | |
Horton | Markers of peripheral androgen action in vivo and in vitro | |
CA3121359A1 (en) | Medication against estrogen-receptor .beta. (er.beta.) positive breast tumor | |
Watson et al. | Testosterone hormone replacement and its alternatives |